Aggressive Breast Cancer Treatments Camp Lejeune NC

The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

Young E Whang, MD
(919) 843-9983
C B 7295 Room 12-038,
Chapel Hill, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Chicago, Pritzker Sch Of Med, Chicago Il 60637
Graduation Year: 1989

Data Provided by:
Lance King LaSsiter
(704) 841-8151
3036 Senna Drive
Matthews, NC
Specialty
Hematology / Oncology

Data Provided by:
Jason Douglas Huff, MD
(336) 716-4380
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 2000

Data Provided by:
Barton Riley Paschal, MD
(828) 254-8232
1 Doctors Dr
Asheville, NC
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Emory Univ Sch Of Med, Atlanta Ga 30322
Graduation Year: 1976
Hospital
Hospital: Park Ridge Hospital, Fletcher, Nc; Mission St Joseph Health Syste, Asheville, Nc; St Josephs Hospital, Asheville, Nc
Group Practice: Asheville Hematology Oncology Assoc Pa; Asheville Hematology Oncology Associates Pa

Data Provided by:
Timothy Eric Bael, MD
(919) 684-5199
25135 Morris Bldg DUMC 3841,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Pittsburgh Sch Of Med, Pittsburgh Pa 15261
Graduation Year: 1999

Data Provided by:
Andrej V Hnatov
(252) 329-0025
801 Wh Smith Blvd
Greenville, NC
Specialty
Radiation Oncology

Data Provided by:
Lillian Paulette Welch, MD
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Va Commonwealth Univ, Med Coll Of Va Sch Of Med, Richmond Va 23298
Graduation Year: 1992

Data Provided by:
Chanchamma A Thannikkary, MD
(252) 537-1717
212 Smith Church Rd
Roanoke Rapids, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Sri Venkatesvara Med Coll, Univ Hlth Sci, Tirupati, Ap, India
Graduation Year: 1972

Data Provided by:
Peter Rubin, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Univ Of Calgary, Fac Of Med, Calgary, Alb, Canada
Graduation Year: 1988

Data Provided by:
Orren Beaty III, DO
(828) 213-1740
50 Doctors Dr Ste 105
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Kirksville Coll Of Osteo Med, Kirksville Mo 63501
Graduation Year: 1988

Data Provided by:
Data Provided by:

Aggressive Breast Cancer Treatments

Provided By:

TUESDAY, Aug. 25 (HealthDay News) -- The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

However, the finding is no reason to ditch the anti-cancer drug, as even the lead researcher emphasized.

"All treatments have risks and benefits," said study author Dr. Christopher Li, an associate member of the Fred Hutchinson Cancer Research Center in Seattle. "We know that the benefits of tamoxifen treatment clearly outweigh the risks. This study adds another risk, but doesn't change the overall balance. If you consider the full balance, for most women the benefits are going to far outweigh the risks."

Li and his colleagues evaluated tamoxifen use among 1,103 breast cancer survivors from the Seattle and Puget Sound area. The women were diagnosed initially with ER-positive breast cancer, the more common and less aggressive form, between the ages of 40 and 70.

Of those women, 369 developed a second breast cancer. Nearly all of those who took the hormonal therapy after surgery or other treatment used tamoxifen for five or more years. The researchers compared those who took tamoxifen with those who did not and found the drug, which blocks estrogen (which helps tumors grow) reduced ER-positive second breast cancers but boosted the risk of ER-negative tumors, which are less common but more aggressive.

"When we looked at the different types of second cancers, tamoxifen only lowered the risk of the more common and less aggressive type of cancer, ER-positive," Li said. "It lowered that by about 60 percent. But it increases the risk of developing ER-negative, the more aggressive cancer, by fourfold."

The study is published online Aug. 25 in the journal Cancer Research.

Exactly why the tamoxifen boosts the risk of ER-negative second cancers is not known, but Li said it could be that prolonged tamoxifen use provides "a competitive advantage for the growth of ER-negative breast cancer cells."

Other experts agreed that the study is no reason to give up on tamoxifen. "The thing we have to remember is tamoxifen saves lives," said Dr. Victor Vogel, national vice president of research at the American Cancer Society.

"Even though the risk of ER-negative goes up, only with five years or more, the risk of ER-positive [second breast cancer] goes down," he said. "We shouldn't lose sight of that."

"I worry people are going to panic if they are taking this drug," said Dr. Minetta Liu, director of translational breast cancer research at the Georgetown University Medical Center, in Washington, D.C. But they should not, she said, because "it has helped a huge number of women."

More information

To learn more about tamoxifen, visit the National Cancer Institute.

Author: By Kathleen Doheny
HealthDay Reporter

SOURCES: Victor Vogel, M.D., national vice president, research, American Cancer Society, Atlanta; Christopher Li, M.D., Ph.D., associate member, Fred Hutchinson Cancer Research Center, Seattle; Minetta Liu, M.D., director, translational breast cancer research, Georgetown University Medical Center, Washington, D.C.; August 25, 2009, Cancer Research

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com